Article DOI: 10.21474/IJAR01/6439
DOI URL: http://dx.doi.org/10.21474/IJAR01/6439

RESEARCH ARTICLE

REVIEW ON: RECENT ADVANCES IN THE STATE OF THE ART OF IN SITU FORMING INJECTABLE HYDROGEL SYSTEMS FOR THERAPEUTIC APPLICATIONS.

*Runa Chakravorty, Dr. Bipul Nath and Sumit Das.
1Girijananda Chowdhury Institute of Pharmaceutical Science, Azara, Guwahati-781017 (Affiliated to Assam Science and Technology University, Jalukbari, Guwahati-781013).

Manuscript Info

Abstract

In situ injectable gelling systems have been extensively investigated with the aim of being applied for minimally invasive drug delivery or injectable tissue engineering. This article explores the injectable in-situ gelling system for prolonged release parenteral drug delivery system and their strategies of preparation. Here, we describe in situ-forming injectable hydrogel systems, prepared using a variety of chemical cross linkers or physical interactions, for application in drug delivery. There are many newer approaches for in situ injectable hydrogels that can be delivered in minimally invasive techniques such as injection, ocular or nasal administration while protecting drugs or cells from the hostile environment. Recently, the Michael addition reaction between thiol and vinyl groups, the click reaction between bis (yne) molecules and multi arm azides, and the Schiff base reaction have been investigated for generation of injectable hydrogels, due to the high selectivity and biocompatibility of these reactions. Non-covalent physical interactions have also been proposed as cross linking mechanisms for in situ forming injectable hydrogels. Hydrophobic interactions, ionic interactions, stereo-complex formation, complementary pair formation, and host-guest interactions drive the formation of 3D polymeric networks. In particular, supramolecular hydrogels have been developed using the host-guest chemistry of cyclodextrin (CD), which allows highly selective, simple, and biocompatible cross linking. Finally, we review the current state of the art of injectable hydrogel systems for application in drug delivery, cell therapy and tissue regeneration.

Copyright, IJAR, 2018. All rights reserved.

Introduction:

Hydrogels are the polymeric materials with three-dimensional networks, which have gained much attention in biomedical fields as carriers for drugs, protein, cells, and others because of their good biocompatibility, solute permeability and tunable release characteristics [1]. The retaining ability of a large amount of water within their structures which results in high water content and soft-surface properties is the character that makes them compromised on the surrounding tissues and leads to a good biocompatibility. Since the development of hydrogels in 1960s, numerous studies on adapting hydrogels as biomaterials have been reported. Especially, the in situ forming hydrogels which usually show sol-to-gel transition at the in-situ site where they are administrated into the body,
exhibit promising potentials for clinic applications. It is more practicable to apply in-situ forming hydrogels to tropical drug delivery, injectable implant, tissue engineering scaffold and so on [2-4]. The drug/cell can be mixed with the aqueous sol for convenient administration. The development of injectable in situ forming drug delivery systems has received a considerable interest over the last decade. In situ gelling systems could potentially alleviate several drawbacks associated with contemporary regenerative medicine approaches and scaffolds. Primarily, they minimize the invasiveness of the open surgical technique and can conform to complex 3D geometries, which is critical in implant drug delivery system, repair of trauma, and regeneration post-tumor resection. More importantly, this allows for delivery of cells and growth factors locally, which could potentially lead to faster and complete regeneration [5].

Injectable hydrogels which can form a gel state after injection into the body are advantageous in biomedical applications due to their high shape ability which can fill irregular defect sites [6], and minimally invasive delivery of a large amount of drug together with bioactive molecules/cells [7] that can eliminate large incision and reduce recovery time, risk of infection, and pain to the patient [8]. Injectable polymers have drawn considerable attention as promising biomaterial for drug delivery and regenerative medicine. Multiple biocompatible and biodegradable polymers are routinely employed as carriers of injectable DDS in order to diminish the drug side-effect, especially for local administration and delivery when used for anticancer chemotherapy.

Many polymeric materials for injectable DDS, such as nanoparticle [9-11], microsphere [12, 13], polymeric micelles [14-15], liposomes [16-18], and hydrogel system [19-20], have been investigated and developed. Although some formations of them have succeeded in clinical applications there still remain many problems that need to be addressed. One of the recent manifestations of stimuli responsive polymers lies in in-situ forming DDS by sol-gel transition for in-situ forming hydrogel because it is feasible to use them as carrier for local administration [21]. As representatives of stimuli-responsive polymer for in-situ forming hydrogel, there are several candidates that include thermoresponsive polymers such as N-isopropyl acrylamide copolymer [22], polyethylene glycol–poly propylene glycol–polyethylene glycol (PEG–PPG–PEG) triblock copolymer [23], and polyethylene glycol–poly N-lactic acid–polyethylene glycol (PEG–PLLA–PEG) triblock copolymer [24]. These thermoresponsive polymers exhibit thermodependent sol–gel transition in aqueous solution via hydrophobic interaction. The advantage of these kinds of polymers is in their ability to avoid toxic cross-linkers which are usually employed to form hydrogel.

However, local injection of thermoresponsive polymers is operationally difficult. Their thermo responsiveness is too sensitive for injection by syringe pump and for this reason they must be cooled down to below the transition temperature before they can be injected. Furthermore, ion-mediated cross-linked hydrogels, such as algnates, which form a gel upon contact with divalent cations, have been widely researched as injectable in-situ forming DDS and tissue engineering because of their biocompatibility [25, 26]. Many alginate derivatives such as lectin-modified alginate [27] and RGD containing alginate [28] have also been synthesized. Despite many of their applications, alginate hydrogels have limited use because of their low shelf lives.

**In-situ** gels are smart polymeric systems which are capable of undergoing rapid sol-to-gel transformation triggered by external stimulus such as temperature modulation, pH change or ionic exchange etc. on instillation from which the drug gets released in a controlled and sustained manner to obtain defined blood levels over a specified time, as well as by avoiding the systemic circulation it reduces toxicity in normal tissues [29, 30]. These are liquid at room temperature but undergo gellation when there is environmental changes like change in pH or temperature, ionic concentration, osmolarity or irradiation[31], magnetic field, ultrasound or visible wavelength in case of photosensitive systems in responsive systems [32, 33].

In contrast to very strong gels, they can be easily applied in liquid form to the site of drug absorption. At the site of drug absorption they swell to form a strong gel that is capable of prolonging the residence time of the active substance. Mostly, biodegradable polymeric materials such as natural polymers including polysaccharides and polypeptides, and synthetic polymers such as PLA and PLGA are used for its formulation [34].

A key requirement of in-situ depot-forming systems for local delivery is the injectability using standard gauge needles either in a vial/syringe or a pre-filled syringe configuration [35]. Ideally, an in-situ gelling system should be a low viscous, free flowing liquid to allow for reproducible administration. In-situ gels are administered by injectable as well as oral, ocular, rectal, vaginal and intra peritoneal routes. [36].
Need of In-situ gelling system:-
In recent years, the development of in situ gel systems has received a considerable attention as polymeric drug delivery systems. The importance of in situ forming matrix systems is related to several advantages such as, for instance, easy application, use of non-toxic carriers, simple and economical elaboration, prolonged residence time and controlled drug release. Moreover these systems avoid painful surgical procedures to insert solid implants [37]. The in situ forming gel systems are designed such that they are fluid prior to injection. Once injected, the formulation responds to a change in the environment to give a high viscosity or solid depot at the injection site. The most studied thermo sensitive polymers are the pluronics which are poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) block copolymers. Those polymers exist as a mobile viscous liquid at reduced temperatures but form a rigid semisolid gel network with an increase in temperature. Unfortunately, pluronic gels are obtained at high polymer concentrations only (between 20 and 30%) and have been shown to erode rapidly [38]. Traditional drug delivery system has got many disadvantages such as high plasma concentration in the systemic circulation when the drug is administered parenterally that result in undesirable side effects [39, 40]. Additionally, many drugs undergo high first pass metabolism and therefore show less bioavailability when given orally. In situ gel formulations offer an interesting alternative for achieving systemic drug effects of parenteral routes, which can be inconvenient for oral route, which can result in unacceptably low bioavailability and passes the hepatic first-pass metabolism, in particular of proteins and peptides[41]. Although, parenteral route offers rapid onset of action with rapid declines of systemic drug level, it requires frequent administration which ultimately leads to patient discomfort. Novel technologies have been developed to overcome these problems by reducing total no of injection throughout the effective treatment. In-situ drug delivery system is one of the most effective controlled release drug delivery systems that have been formulated using injectable and biocompatible smart polymer. This system offers attractive opportunities and provides sustained release of drug with less pain and less invasive technique thereby reducing frequency of administration and improving patient compliance.

Advantage:-
1. In–situ gel offers sustained and prolonged action in comparison to conventional drug delivery
2. Production of such device is simple and thus minimizes manufacturing costs and associated investments.
3. Ease of administration and improved patient compliance.
4. Deliverance of accurate dose
5. In situ gels can also be engineered to exhibit bioadhesiveness to facilitate drug targeting, especially through mucus membranes, for non-invasive drug administration.
6. In situ gels offer an important “stealth” characteristic in vivo, owing to their hydrophilicity which increases the in vivo circulation time of the delivery device by evading the host immune response and decreasing phagocytic activities.
7. Reduced toxic and side effects as the drug is delivered locally at the site of action therefore no harms to the healthy tissues can be seen.

Disadvantage:-
1. It requires high level of fluids.
2. It leads to degradation due to storage problems.

Approaches In The Design Of In Situ-Forming Injectable Hydrogels:-
Injectable hydrogels prepared by chemical cross linking:-
Michael addition for formation of injectable hydrogels:-
Michael addition is the nucleophilic addition of a carbanion or a nucleophile, such as thiols and amines, to an α, β unsaturated carbonyl compound [42]. The reaction is highly selective under physiological conditions, without involving toxic reagents and side products. Accordingly, this reaction has been widely exploited for the preparation of injectable hydrogels for biomedical applications. For example, the Michael addition reaction can occur between thiol and vinyl sulfone (VS) or aminooethylmethacrylate (AEMA). As a polymer backbone, synthetic and natural polymers have been used for the preparation of hydrogels, such as poly (ethylene glycol) (PEG), collagen, HA, and heparin [43-47]. Cells and biopharmaceuticals can be encapsulated within such a hydrogel by simple mixing with the polymer precursor solutions. Extracel™ is one of the typical injectable hydrogels created by Michael addition between a thiol modified carboxymethyl HA and gelatin modified with diacrylated PEG [43, 48-50].
Click reaction for formation of injectable hydrogels:-
Click chemistry is a Cu (I)-catalyzed reaction between azide and terminal acetylene groups, forming 1, 2, 3-triazoles [51, 52]. This reaction is widely employed for biomedical applications, because of the high yield, region specificity, absence of toxic byproducts, and rapid reactivity under physiological conditions. Using click chemistry, various hydrogels have been developed for drug delivery and tissue engineering applications [53-56]. A polymeric 3D network has been fabricated using a dipolar cyclo addition reaction between the two types of derivatives in the presence of a catalytic amount of Cu (I), at room temperature. Recently, copper-free click chemistry has also been developed using azide-alkyne cyclo addition between difluorinated cyclooctyne (DIFO3) and azide, and applied to in situ hydrogel formation [57, 60]. Simple mixing of the polymer precursor solutions with a cell suspension resulted in hydrogel formation via the highly specific click reaction of azide with acetylene, encapsulating the cells. In addition, post-modification of the hydrogel on demand, can be performed by subsequent functionalization of the remaining azide or acetylene group.

Schiff base reaction for formation of injectable hydrogels:-
Injectable hydrogels can be prepared by a Schiff base reaction between an amine group and an aldehyde group, without additional chemical cross linking reagents. The residual functional groups within the hydrogel can be used for covalent conjugation of therapeutic molecules or additional cross linking. HA, chitosan, dextran, chondroitin sulfate, and poly (vinyl alcohol) have been used for the preparation of hydrogels via the Schiff base reaction [59-61]. The gelation time and physical properties of these hydrogels are dependent on the ratio of the amine and aldehyde groups. Although the cells entrapped in these hydrogels have been reported to maintain their normal morphology, aldehyde groups can react with other amine groups in biomolecules of cells in the body during the cross linking reaction.

Enzyme-mediated injectable hydrogels:-
Tyramine-conjugated polymers have been used for in situ hydrogel formation in the presence of H2O2 and horseradish peroxidase [62-65]. The enzymatically crosslinked hydrogels can be prepared within 10 min, depending on the polymer concentration and the enzyme/tyramine ratio. Polymer-tyramine hydrogels with high elasticity have been used as drug delivery depot systems [63] and tissue engineering scaffolds [61-65].

Photo-cross linked injectable hydrogels:-
Methacrylated polymers have been used for in situ hydrogel formation by photo-crosslinking with a photo initiator [66]. The hydrogel precursor solution is injected into the body and is then exposed to visible or ultraviolet (UV) light. Photo-crosslinking has also been used to improve the mechanical properties and stability of physically crosslinked hydrogels [67, 68]. For example, methacrylic acid was introduced into thermosensitive polymers or electrostatically crosslinked hydrogels. The thermosensitive photopolymerized hydrogels demonstrated improved mechanical properties. However, the practical applications of photo-cross linked hydrogels are limited due to the possible toxicity of photoinitiators, the long exposure time, and the short penetration depth of light sources [69, 70].

Injectable hydrogels prepared by electrostatic interaction:-
Alginate-based injectable hydrogels:-
Alginate is an anionic polysaccharide derived from sea algae. Alginate hydrogels are formed by simple mixing of alginate solutions with divalent cations, such as Ca2+, Mg2+ and Ba2+. Alginate-based hydrogels have been widely used for drug delivery [71], cell therapy [72, 73], and tissue engineering [62-65]. They have been used in clinical trials and are a component of FDA approved medical products. The formation and the mechanical strength of alginate-based hydrogels can be controlled by changing the concentration and the type of cation added. For example, the rate of alginate hydrogel formation increased with increasing total calcium content in the case of CaCO3/d-glucono-δ-lactone (GDL) and CaSO4/CaCO3/GDL systems [74]. The mechanical properties of the alginate hydrogels were improved with increasing alginate concentration, total calcium content, molecular weight, and glucuronic acid content of the alginate. However, alginate hydrogels formed by ionic interaction are not stable in the body, because ionic molecules diffuse out from the hydrogels into the body fluid [73-75]. In addition, the formation of alginate hydrogel is difficult to control, and the hydrogel has poor cell adhesion [76]. To improve the stability and mechanical properties of this type of hydrogel, highly stretchable and tough alginate hydrogels have been prepared by additional covalent cross linking [77, 78].
Chitosan-based injectable hydrogels:-
Chitosan is an alternating copolymer of 2-acetamido-2-deoxy-β-d-glucopyranose and 2-amino-2-deoxy-d-glucopyranose derived from naturally occurring chitin. Chitosan can form a hydrogel complex with polyanionic molecules via electrostatic interaction [79]. Temperature and pH-responsive chitosan-based hydrogels have been prepared with polyol-salts possessing a single anionic head, such as glycerol-, sorbitol-, fructose-, or glucose-phosphate salts (polyol- or sugar-phosphate) [80-83]. The driving force behind hydrogel formation includes hydrogen bonding, electrostatic interaction, and hydrophobic interaction between chitosan and polyol-phosphate salts. The chitosan solution remains liquid at physiological pH and turns into a hydrogel at body temperature. Drugs and cells can be easily entrapped within the hydrogel by mixing them with the precursor solution at low temperature prior to injection.

Stimuli-responsive injectable hydrogels:-
Temperature-responsive injectable hydrogels:-
Some polymers undergo solubility changes and phase transitions in response to environmental temperature [84, 85]. This threshold is referred to as the lower critical solution temperature (LCST) [86]. For example, poly (N-isopropylacrylamide) (PNIPAAm) undergoes phase transition at temperatures above 32°C in an aqueous solution. Because the LCST of PNIPAAm is increased by copolymerization with a hydrophilic polymer, in situ gelation temperature can be adjusted to body temperature [84]. In addition, some amphiphilic polymers were used for hydrogel formation, by micellar packing, in response to temperature changes [87]. Linear and star shaped block copolymers composed of central hydrophilic polyethylene oxide (PEO) and terminal PNIPAAm, showed a temperature-responsive behavior, forming relatively strong injectable hydrogels [86]. Recently, biodegradable temperature-responsive hydrogels were developed for biomedical applications by combining non-biodegradable PNIPAAm and biodegradable polymers [88-90]. The HA-g-PNIPAAm conjugate forms a hydrogel network, exhibiting reversible temperature-responsive solubility [89]. The degradation rate, swelling ratio, and cytocompatibility of the hydrogels can be controlled by changing the weight ratio of PNIPAAm to HA for tissue engineering applications. A PEO-PPO-PEO triblock copolymer, under the tradename of Pluronic®, is one of the most commonly used thermosensitive hydrogels for biomedical applications. Dehydration and increasing hydrophobicity of the PPO block with increasing temperature results in micelle formation, which is the driving force for in situ hydro-gel formation. This hydrogel formation is dependent on the concentration and temperature of the polymer precursor solution. Pluronic® with a different composition and molecular weight of copolymer has been used for applications in drug delivery, gene delivery, tissue adhesion prevention, and tissue engineering [91]. However, Pluronic® systems have the disadvantages of having weak mechanical strength and being non-biodegradable. Biodegradable PEG-PLGA-PEG also forms a thermoresponsive hydrogel similar to the PEO-PPO-PEO triblock copolymer systems [92]. Despite the wide clinical exploitation of PLGA based copolymers with FDA approval, they are known to cause harmful side effects to biomolecules, cells, and tissues in some cases after they are degraded to acidic monomers [93, 94]. To overcome these issues, porous devices, microparticles, and hydrogels have been developed using this type of polymers [94].

Dual-responsive injectable hydrogels:-
The main disadvantage of physically cross linked thermo sensitive hydrogels is their weak stability and mechanical properties in the body. Accordingly, dual-responsive hydrogels have been developed to alleviate these problems. For example, temperature and pH-responsive hydrogels have been developed using PNIPAAm-based copolymers. PNIPAAm is copolymerized with pH-responsive segments, such as poly (propylacrylic acid) (PPAA), poly (N-isopropylmaleic acid) (PNIPMAA), and poly (methacrylic acid) (PMAA) [95]. These synthetic polymers are not only temperature responsive but also significantly pH responsive due to the presence of carboxyl groups. In addition, temperature and pH-responsive hydrogels have been prepared with multiblock copolymers [96]. The pH-responsive sulfamethazine oligomers (SMO) have been conjugated to both ends of thermoresponsive poly (ε-caprolactone-co-lactide)-PEG-poly (ε-caprolactone-co-lactide). The resulting SMO–PCLA–PEG–PCLA–SMO multiblock copolymer solution shows a reversible sol-gel transition at pH 7.2 and body temperature. The mechanism of hydrogel formation is the hydrophobic interaction between SMO and PCLA blocks. These temperature and pH (dual) responsive hydrogels have enhanced mechanical strength and prevent gelation of the precursor solution in the needle during injection into the body. Other dual-responsive hydrogel systems that enhance the mechanical properties of physically cross linked hydrogels have also been developed using photo and temperature responsive hydrogel systems [97, 98].
Supramolecular injectable hydrogels prepared by self-assembly:-
Self-assembling injectable hydrogels by complementary binding:-
Self-assembling hydrogels have been developed using various complementary bindings, such as ligand-receptor pairs [99-101], antigen-antibody pairs [102-104], and base-pairing interactions [105-107]. Because ligand-receptor pairs have an extremely high binding affinity, the formation of a complex between a receptor and a ligand can be used to drive formation of injectable hydrogels. For example, a streptavidin-biotin pair has been used for the preparation of injectable hydrogels. PLA-PEG-biotin microparticles have been cross linked with avidin to generate 3D porous matrices that self-assemble at the injection site. In addition, multiple repeats of tryptophan rich domains and proline rich peptide domains have been used for hydrogel formation [102]. The amount of crosslinking protein affected the hydrogel formation rate, as well as the physical strength of the hydrogels. Moreover, growth factors could be added to the hydrogel precursor solution to promote cellular functions within the hydrogel. Antibody-antigen interaction has also been used for the formation of an injectable 3D network [104-106]. Simple mixing of antibody-conjugated polymer and antigen-grafted polymer solutions can result in hydrogel formation. Treatment with free antigen or free antibody also affects the physical properties of these hydrogels. In addition, self-assembling hydrogels have been prepared using three complementary branched DNA sequences [105-107]. However, the relative difficulties in mass production and chemical modification of biomolecules, as well as the potential safety issues involved, should be addressed to expand the applications of these hydrogels to therapeutic purposes.

Self-assembling injectable hydrogels by host-guest interaction of cyclodextrin:-
As an alternative to biological complementary binding pairs, self-assembling hydrogels have been developed using host-guest interaction of the cyclodextrin (CD) family. CDs are series of natural cyclic oligosaccharides composed of six, seven, or eight d-glucopyranoside units (α, β, and γ-CD). They have a hydrophobic inner cavity, by which they can generate an inclusion complex with other guest molecules, such as PEG, adamantane, and cholesterol [108]. Recently, injectable hydrogels that make use of an inclusion complex of CD have emerged as another series of promising physical hydrogels that can be used in various biomedical applications [109-111]. PEG can penetrate the inner cavity of α-CD to generate an inclusion complex. Injectable hydrogels have been created by mixing high molecular weight PEG and α-CD in aqueous solution [109]. This type of hydrogel is reversibly thixotropic and non-degradable high molecular weight PEG is not ideal for in vivo applications. To improve the stability of the hydrogel, PEO-PEG was used to make a complex with α-CD, β-CD and adamantane, and β-CD and cholesterol pairs have also been investigated for the preparation of injectable hydrogels [110-112]. However, CD-based hydrogels have an intrinsic limitation in in-vivo applications, due to the low binding affinity of CD to guest molecules and the low stability of the resulting hydrogels in the body [112].

Evaluation And Characterization Parameters For Injectable In-Situ Gels:-
Clarity:-
The clarity of formulated solutions determined by visual inspection under black and white background [32, 113]

Texture analysis:-
The consistency, firmness & cohesiveness of in situ gel are assessed by using texture profile analyzer which mainly indicated gel strength & easiness in administration in vivo higher value of adhesiveness of gel are needed to maintain an intimate contact with mucus surface [32, 113]

pH of gel:-
The pH can be determined using pH meter. The formulation is taken in beaker & 1ml NaOH added drop wise with continuous stirring and pH is checked by using pH meter [114].

Inner morphology of the dual cross linked hydrogels:-
The inner morphology of the dual cross linked hydrogels are investigated using scanning electron microscope. Briefly, the lyophilized hydrogel samples are surface gold sprayed and observed using SEM at an accelerating voltage of 10 kV. At last, average pore diameter and pore area are quantified using Image software [115].

Gel-Strength:-
This parameter can be evaluated using a rheometer. Depending on the mechanism of the gelling of gelling agent used, a specified amount of gel is prepared in a beaker, from the sol form. This gel containing beaker is raised at a certain rate, so pushing a probe slowly through the gel. The changes in the load on the probe can be measured as a function of depth of immersion of the probe below the gel surface [116].
**Gelling capacity:**-
In situ gel is mixed with tissue fluid in the specific proportion to find out gelling capacity of injectable product. The gelation assessed visually by noting the time for & time taken for dissolution of the formed gel [117].

**Gelation temperature and in situ gel formation studies:**-
One millilitre of the polymeric system is transferred in a small bottle; 1ml deionized water is added and incubated at 37.4 ºC. Separately 1 ml of the polymeric system is introduced to dialysis against PBS pH 7.4 in cellulose tube at 37.4 ºC for 120 min. The system is monitored every 15 min to see if gelation has occurred. For the in vivo evaluation of the system, 0.1-0.3 ml of the polymeric composition is injected subcutaneously into the back of the neck or abdominal area of the rats. After 120 min the marked area is opened through a surgery operation and the fate of the hydrogels are evaluated [118].

**Rheological studies:**-
The viscosity measured by using Brookfield viscometer, cone & plate viscometer [119].

**Water content and swelling studies:**-
The prepared dual crosslinked hydrogels are transferred to beakers that containing 37 ºC distilled water to investigate their water content. The swollen hydrogels are taken out and surface water blotted at determined time point to weigh their mass until reaching a constant mass. The swollen hydrogels are lyophilized and the dry gel is also weighed. Equilibrium water content (EWC) and swelling ratio are determined by the following equations [120, 121]:

\[ \text{EWC} \% = \frac{W_e - W_d}{W_e} \times 100 \]  
\[ \text{Swelling Ratio} \% = \frac{W_s - W_d}{W_d} \times 100 \]

In equation (1) \( W_e \) is weight at equilibrium swollen state and \( W_d \) is dry weight. In equation (2) \( W_s \) is the swollen weight at given time and \( W_d \) is dry weight.

**In vitro degradation studies:**-
Degradation of hydrogels is assessed at 37ºC with continuous shaking in a shaking water bath and simulated body fluid (SBF) is changed every two days. At predetermined time intervals (1-6 weeks), hydrogels are rinsed with SBF and lyophilized. The vacuum dried hydrogels are weighed and weight loss percentage is calculated by the formula [122]:

\[ \text{Weight Loss} \% = \frac{W_i - W_d}{W_i} \times 100 \]

Here \( W_i \) is initial weight of the sample, \( W_d \) is dry weight of the sample.

**In-Vitro Drug Release Studies:**-
The drug release studies are carried out by using the plastic dialysis cell. The cell is made up of two half cells, donor compartment and a receptor compartment. Both half cells are separated with the help of cellulose membrane. The sol form of the formulation is placed in the donor compartment. The assembled cell is then shaken horizontally in an incubator. The total volume of the receptor solution can be removed at intervals and replaced with the fresh media. This receptor solution is analyzed for the drug release using analytical technique [123, 124]

**Histopathological studies:**-
For the histological studies, the animals are sacrificed and the intact shaved skin of injection area and the left and right testicles are isolated and washed with normal saline to remove blood and are fixed for 24 h at 4 ºC, and then dehydrated with a 50-100% v/v ethanol series with a final change in xylene, before embedding in paraffin. Five micrometers sections are cut and mounted onto positively charged slides, which is heated at 55 ºC to ensure adherence of the sections. For staining, sections are dewaxed in xylene, then rehydrated in a 100-50% ethanol series, and quickly rinsed in distilled water. The sections are observed under high magnification (>_100/x400) light microscope to check histopathological changes [125, 126].

**Sterility testing:**-
Sterility testing is carried out as per the IP 1996. The formulation is incubating for not less than 14 days at 30-35ºC in the fluid thioglycolate medium to find the growth of bacteria & at 20-25ºC in Soya bean casein digest medium to find the growth of fungi in formulation [127].
Accelerated stability Studies:-
Formulations are placed in ambient colour vials and sealed with aluminium foil for a short term accelerated stability study at 40±2°C and 75±5% RH as per International Conference on Harmonization (ICH) states Guidelines. Samples are analyzed every month for clarity, pH, gelling capacity, drug content, rheological evaluation, and in vitro dissolution [128]

In vivo studies:-
The experiment is performed in accordance to the guidelines of international animal studies approved by the ethics committee. Male rats 8 weeks old, 250-300 gram weight that are given food and water ad libitum are used. During the whole study, uniform feed and free water is supplied. In this study the serum testosterone level of four groups (A, B, C, and D) of male rats (n = 6) at each time intervals after treatment is compared with the initial base line of the same group. Group A received no injection to verify the natural fluctuation of serum testosterone concentration during the study. Group B received µl injection of drug in pure form. Group C received µl injection of the in situ gel forming system containing drug. Group D received 100 µl injection of the drug free in situ gel forming system as placebo. All samples are injected subcutaneously at the back of the neck of the rats. The level of serum testosterone is determined for 3 days as testosterone base line in each group before starting the study. Blood samples are collected at 3 and 6 h in the first day and on days 2, 3, 7, 14, 21, 28, 35, 42 directly from the heart of the animals. The blood samples are centrifuged for 15 min at 14,000 rpm to separate serum. The serum testosterone level is determined by Liaison testosterone kit as direct chemiluminescence immunoassay [129, 130]. Results are expressed as mean ± standard error (SE), or mean ± standard deviation (SD), and significance between two groups is determined by Student t-test.

Conclusion:-
In this review, we have summarized recent progress in the art of design of in situ injectable gelling systems. The gelling process should occur under mild conditions for biomedical applications without damaging incorporated pharmaceuticals and cells. Therefore, cross links have been prepared in aqueous systems by benign chemical reactions such as redox/photo-polymerization, Michael addition, click reactions, enzymatic reactions; or physicochemical association of the molecules including thermo gelation, ion-induced gelation, inclusion complex formation, stereo complex formation, and complementary binding processes. Compared to the conventional therapy, the injectable hydrogel systems provide some advantages, such as reduced toxicity in normal tissues, localized and sustained delivery of the drugs in the tumor vicinity, more efficient cell apoptosis, as well as tumor growth inhibition. Injectable hydrogels prepared by chemical cross linking demonstrate good mechanical properties, but in vivo applications have been limited due to the possible cytotoxicity of the reactive chemical cross linkers. In contrast, injectable hydrogels prepared by physical cross linking can be formed easily without reactive chemical reagents, but the hydrogels have poor stability and mechanical properties in the body. Supramolecular injectable hydrogels are fabricated by self-assembly of receptor-ligand pairs, complementary pairs, and host-guest pairs.

Future Scope:-
This smart polymeric injectable gelling system has come out as a promising drug delivery system mainly for the very potent drugs like anticancer molecules and protein and peptide drugs. The manufacturing process is very simple which lessen the cost of the product which are otherwise very expensive. Also they possess the tremendous capability to deliver the drug effectively to the site with minimal or no systemic side effects. It can be formulated into a suitable formulation for easy injection prior to in-situ gelation and show controlled release. Therefore it can be used for effective delivery of anti cancer molecules to the site with no or very less systemic bioavailability and no harm to the healthy organs. Future use of biodegradable and water soluble polymers for the in-situ gel formulations can make them more acceptable and excellent drug delivery systems for use of injectable drug depots for systemically active compounds. The extensive work demonstrating the use of these materials for delivery of insulin, a signaling hormone that acts on systemic sites in the liver and skeletal muscle, points to an obvious application for skin-associated delivery of depots containing systemically active drugs. In particular, there is logical application for these technologies in the delivery of biologics, which remain very difficult to administer orally, in order to enable therapeutic use by patients at home that would otherwise require infusion in a clinic. Another application for injectable biomaterials that aligns with standard practice is in vaccination. Hormonal therapy has been the main treatment of advanced and metastatic prostate and breast cancers. Initially luteinizing hormone-releasing hormone (LHRH) agonist therapy consisted of daily subcutaneous injections of LHRH agonists (e.g., leuprolide, goserelin, triptorelin) are successful line of therapy.
References:

1. Fakhari A, Subramony JA: Engineered in-situ depot-forming hydrogels for intratumoral drug delivery. Journal of controlled release 2015; 220:465–475.
2. Kempe S, Mader K: In situ forming implants- an attractive formulation principle for parenteral depot formulations. Journal of Controlled Release 2012; 161:668–679.
3. Almeida H, Amaral MH, Lobao P and Lobo JM: In situ gelling systems: a strategy to improve the bioavailability of ophthalamic pharmaceutical formulations. Drug Discovery Today 2014; 19:400–412.
4. Wang XQ, Liu GY, Ma JLG, Guo S, Gao L, Jia Y, Li X and Zhang Q: In situ gel-forming system: an attractive alternative for nasal drug delivery. Critical Review Therapy Drug Carrier System. 2013; 30(5):411-34.
5. Russo T, Tunesi M, Giordano C, Gloria A and Ambrosio L: Hydrogels for central nervous system therapeutic strategies. Process Instrumentation Mechanical Engineering Hydrogel 2015; 229:905–916.
6. Li Y, Rodrigues J, & Tomás H: Injectable and biodegradable hydrogels: Gelation, biodegradation and biomedical applications. Chemical Society Reviews, 41(6), 2193–2221.
7. Choi SM, Lee Y, Son JY, Bae J W, Park KM, & Park KD: Synthesis and characterization of in situ gellable poly (glycerol sebacate)-co-poly(ethylene glycol) polymers. Macromolecular Research 2017; 25(1): 85–91.
8. Bae KH, Wang LS, & Kurisawa M: Injectable biodegradable hydrogels: Progress and challenges. Journal of Materials Chemistry 2013;1(40): 5371.
9. Panyam J, Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Advanced Drug Delivery 2003; 55: 329–347.
10. Bannon-Peppas L, Blanchette JO: Nanoparticle and targeted system for cancer therapy. Advanced Drug Delivery Review 2004; 56:1649–1659.
11. Barraud L, Merle P, Soma E, Lefrancois L, Guarret S, Chevallier M, Dubernet C, Couvreur P, Trepo C and Vitiitski L: Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. Journal of Hepatology 2005; 42(5): 736–743.
12. Kakinoki S, Yasuda C, Kaetsu I, Yukutake K, Nakayama M, Fujie S, Kuroda D, Kato M, and Ohyanagi H: Preparation of in situ gelable poly(lactic acid) microsphere containing the angiogenesis inhibitor TNP-470 with medium-chain triglyceride and the in vitro evaluation of release profiles. European Journal of Pharmaceutics and Biopharmaceutics 2003; 55:155–160.
13. Freiberg S, Zhu X: Polymer microsphere for controlled drug release. International Journal of Pharmaceutics 2004; 282: 1–18.
14. Nishiyama N, Bae Y, Miyata K, Fukushima S, Kataoka K: Smart polymeric micelles for gene and drug delivery. Drug Discovery Today 2005; 2:21–26.
15. Hruby M, Konak C, Ulbrich K: Polymeric micellar pH-sensitive drug delivery system for doxorubicin. Journal of Controlled Release 2005; 103:137–148.
16. Goyal P, Goyal K, Kumar S,G, Singh A, Katare OP, Mishra DN: Liposomal drug delivery systems – clinical applications. Acta Pharmaceutica 2005; 55:1–25.
17. Kaneda Y: Virosomes: Evolution of the liposome as a targeted drug delivery system. Advanced Drug Delivery Reviews 2000; 43: 197–205.
18. Saul JM, Annapragada A, Natarajan JV, and Bellamkonda RV: Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. Journal of Controlled Release 2003; 92: 49–67.
19. He H, Cao X, Lee LJ: Design of a novel hydrogel-based intelligent system for controlled drug release. Journal of Controlled Release 2004; 95: 391-402.
20. Hoffman AS: Hydrogels for biomedical applications. Advanced Drug Delivery Reviews. 2002; 54:3–12.
21. Packhauer CB, Schnieders J, Oster CG, Kissel T: In situ forming parenteral drug delivery systems: an overview. European Journal of Pharmaceutics and Biopharmaceutics 2004; 58: 445–455.
22. Ibusuki S, Fuji Y, Isomoto Y, Matsuda T: Tissue-engineered cartilage using an injectable and in situ gelable thermoresponsive gelatin: fabrication and in vitro performance. Tissue Engineering 2003; 9:371–384.
23. Malmsten M, Lindman B: Self-assembly in aqueous block copolymer solutions. Macromolecules 1992; 25: 5440–5445.
24. Gariepy E.R., Leroux J.C: In situ-forming hydrogels review of temperature-sensitive systems. European Journal of Pharmaceutics and Biopharmaceutics 2004; 58: 409–426.
25. Draget K.I., Bræk K.I., and Smidsrd O: Alginate based new materials. International Journal of Biological Macromolecules 1997; 21:47–55.
26. Lee KY, Mooney DJ: Hydrogels for tissue engineering. Chemical Reviews. 2001; 101:1869–1879.
27. Sultzbaugh KJ, Speaker TJ: A method to attach lectins to the surface of spermine alginate microcapsules based on the avidin biotin interaction. Journal of Microencapsulation 1996 13:363–376.
28. Rowley JA, Madlambayan G and Mooney DJ: Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 1990; 20: 45–53.
29. Norouzi M, Nazari B and Miller DW: Injectable hydrogel-based drug delivery systems for local cancer therapy, Drug Discovery Today. 21: 1835-1847.
30. Patil PR, Shaikh SS, Shivsharan KJ and Shahi SR: In situ gel: a novel drug delivery system. Indo American Journal of Pharmaceutical Research 2014; 11: 5406-5413.
31. Fakhari A. and Subramony JA: Engineered in-situ depot-forming hydrogels for intratumoral drug delivery. Journal of Controlled Release 2015; 220:465–475.
32. Makó A., Csóka G, Pásztor E, Marton S, Horvai G and Klebovich I: Formulation of thermoresponsive and bioadhesive gel for treatment of oesophageal pain and inflammation. European Journal of Pharmaceutics and Biopharmaceutics 2009; 72: 260–265.
33. Madan M, Bajaj A, Lewis S., Udupa N. and Baig J. A.: In Situ Forming Polymeric Drug Delivery Systems. Indian Journal of Pharmaceutical Science. 2009; 71 (3): 242-251.
34. Hatefi A, Amsden B; Biodegradable injectable in situ forming drug delivery systems. Journal of Controlled Release 2002; 80: 9–28.
35. Packhaeuser CB, Schnieders J, Oster CG, kissel T: In-situ forming parenteral drug delivery system: an overview. European journal of pharmaceutics and biopharmaceutics 2004; 58:445-455.
36. Berger J, Reist M, Mayer JM, Felt O, Peppas N, Gurny R : Structure and interactions in covalently and ionically crosslinked chitosan hydrogels for biomedical applications. European Journal of Pharmaceutics and Biopharmaceutics 2004; 57: 19–34.
37. Hatefi A, Amsden B: Biodegradable injectable in situ forming drug delivery systems; Journal of Controlled Release 2002; 80: 9–28.
38. Matschke C, Isele U, Van Hoogevest P, and Fahr A. Sustained release injectables formed in situ and their potential use for veterinary products. Journal of Control Release 2002; 85:1-15.
39. Chaocheng Lu a, Mengjiao Liu a, Hualin Fu a, Wei Zhang a, Guanngeng Peng b, Yanli Zhang a, Hang Cao a, Li Luo; Novel thermosensitive in situ gel based on poloxamer for uterus delivery. European Journal of Pharmaceutics and Biotherapeutics 2015; 77:24–28.
40. Weinberg B.D., Blanco E., Gao J: Polymer implants for intratumoral drug delivery and cancer therapy. Journal of Pharmaceutical Science.2008; 97:1681–1702.
41. Crawford J, Dale D.C., Lyman G.H.: Chemotherapy-induced neutropenia. Cancer 2004; 100:228–237.
42. Miyazaki S., Aoyama H, Kawasaki N, Kubo W, Attwood D: In-situ gelling gellan formulations as vehicles for oral drug delivery. Journal of Controlled Release 1999; 60:287-295.
43. Mather BD, Viswanathan K, Miller KM, Long TE: Michael addition reactions in macromolecular design for emerging technologies. Progress in Polymer Science 2006; 31:487–531.
44. Zheng Shu X, Liu Y, Palumbo FS, Luo Y, Prestwich GD. In situ crosslinkable hyaluronan hydrogels for tissue engineering. Biomaterials 2004; 25:1339–1348.
45. Jin R, Moreira Teixeira LS, Krouwels A, Dijkstra PJ, van Blitterwijk CA, Karperien M, Feijen J: Synthesis and characterization of hyaluronic acid-poly(ethylene glycol) hydrogels via Michael addition: an injectable biomaterial for cartilage repair. Acta Biomaterialia 2010; 6:1968.
46. Tae G, Kim YJ, Choi WI, Kim M, Stayton PS, Hoffman AS: Formation of a novel heparin-based hydrogel in the presence of heparin-binding biomolecules. Biomacromolecules 2007; 8:1979–1986.
47. Kim M, Lee JY, Jones CN, Revzin A, Tae G. Heparin-based hydrogel as a matrix for encapsulation and cultivation of primary hepatocytes. Biomaterials 2010; 31:3596–603.
48. Yang JA, Kim H, Park K, Hahn SK: Molecular design of hyaluronic acid hydrogel networks for long-term controlled delivery of human growth hormone. Soft Matter 2011; 7:868–70.
49. Cai S, Liu Y, Zheng SX, Prestwich GD: Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growthfactor. Biomaterials 2005; 26:6054–67.
50. Liu Y, Shu XZ, Prestwich GD: Reduced postoperativeintra-abdominal adhesions using Carbylan-SX, a semisynthetic gly-cosaminoglycan hydrogel. Fertil Steril 2007; 87:940–8.
51. Shu XZ, Liu Y, Palumbo F, Prestwich GD: Disulfide-crosslinked hyaluronan–gelatin hydrogel films: a covalent mimic of the extracellular matrix for in vitro cell growth. Biomaterials2003; 24:3825–34.
52. Binder WH, Sachsenhofer R: 'Click’ chemistry in polymer and materials science. Macromolecular Rapid Communications 2007; 28:15–54.
53. Nimmo CM, Shoichet MS: Regenerative biomaterials that “click”: simple, aqueous-based protocols for hydrogel synthesis, surface immobilization, and 3D patterning. Bioconjugate Chemistry 2011; 22:2199–209.
54. Van Dijk M, van Nostrum CF, Hennink WE, Rijkers DT, Liskamp RM: Synthesis and characterization of enzymatically biodegradable PEG and peptide-based hydrogels prepared by click chemistry Biomacromolecules 2010; 11:1608–14.

55. Malkoch M, Vestberg R, Gupta N, Mesplugue L, Dubois P, Mason AF, Hedrick JL, Liao Q, Frank CW, Kingsbury K, Hawker CJ: Synthesis of well-defined hydrogel networks using click chemistry. Chemical Communication 2006; 2774–6.

56. Johnson JA, Lewis DR, Diaz DD, Finn MG, Koberstein JT, Turro NJ: Synthesis of degradable model networks via ATRP and click chemistry. Journal of the American Chemical Society 2006; 128:6564–5.

57. DeForest CA, Anseth KS: Cytocompatible click-based hydro-gels with dynamically tunable properties through orthogonal photo conjugation and photo cleavage reactions. Nature Chemistry 2011; 3:925–31.

58. DeForest CA, Polizzotti BD, Anseth KS: Sequential click reactions for synthesizing and patterning three-dimensional cell microenvironments. Nature Materials 2009; 8:659–64.

59. Ossipov DA, Brannvall K, Forsberg-Nilsson K, Hilborn J: Formation of the first injectable poly(vinyl alcohol) hydrogel by mixing of functional PVA precursors. Journal of Applied Polymer Science 2007; 106:60–70.

60. Tan H, Chu CR, Payne KA, Marra KG: Injectable in situ forming biodegradable chitosan-hyaluronic acid based hydrogels for cartilage tissue engineering. Biomaterials 2009; 30:2499–506.

61. Wang DA, Varghese S, Sharma B, Strehin I, Ferrier M, Gorham J, Fairbrother DH, Cascio B, Elisseef JH. Multifunctional chondroitin sulphate for cartilage tissue biointegration. Nature Materials 2007; 6:385–92.

62. Jia X, Yeo Y, Clifton RJ, Jiao T, Kohane DS, Kobler JB, Zeitels SM, Langer R: Hyaluronic acid-based microgels and microgel networks for vocal fold regeneration. Biomacromolecules 2006; 7:3336–44.

63. Maia J, Ferreira L, Carvalho R, Ramos MA, Gil MH: Synthesis and characterization of new injectable and degradable dextran-based hydrogels. Polymer 2005; 46:9604–14.

64. Kim KS, Park SJ, Yang JA, Jeon JH, Bhang SH, Kim BS, Hahn SK: Injectable hyaluronic acid–tyramine hydrogels for the treatment of rheumatoid arthritis. Acta Biomaterialia 2011; 7:666–74.

65. Jin R, Moreira Teixeira LS, Dijkstra PJ, van Blitterswijk CA, Kerperien M, Feijen J: Chondrogenesis in injectable enzymatically crosslinkedheparin/dextran hydrogels. Journal of Controlled Release 2011; 152:186–95.

66. Jin R, Moreira Teixeira LS, Dijkstra PJ, Kerperien M, van Blitter-swijk CA, Zhong ZY, Feijen J: Injectable chitosan-based hydrogels for cartilage tissue engineering. Biomaterials 2009; 30:2544–51.

67. Elisseff J, Anseth K, Sims D, McIntosh W, Randolph M, Langer R: Transdermal photopolymerization for minimally invasive implantation. Proceedings of the National Academy of Science USA 1999; 96:3104–7.

68. Chou AI, Akintoye SO, Nicoll SB; Photo-crosslinked alginate hydro-gels support enhanced matrix accumulation by nucleus pulposus cells in vivo. Osteoarthritis Cartilage 2009; 17:1377–84.

69. Pereira IHL, Ayres E, Patricio PS, Goes AM, Gomide VS, Junior EP, Orefice RL. Photopolymerizable and injectablepolyurethanes for biomedical applications: synthesis and bio-compatibility. Acta Biomaterialia 2010; 6:3056–66.

70. Ovsianikov A, Malinauskas M, Schlie S, Chichkov B, Gittard S, Narayan R, Lobler M, Sternberg K, Schmitz KP, Havercich A: Three-dimensional laser micro- and nano-structuring of acrylated poly(ethylene glycol) materials and evaluation of their cytotoxicity for tissue engineering applications. Acta Biomaterialia 2011; 7:967–74.

71. Williams CG, Malik AN, Kim TK, Manson PN, Elisseef JH: Variable cytocompatibility of six cell lines with photo initiators used for polymerizing hydrogels and cell encapsulation. Biomaterials 2005; 26:1211–8.

72. Stevens MM, Qad idol LF, Langer R and Shastri VP: A rapid-curining alginate gel system: utility in periosteum-derived cartilage tissue engineering. Biomaterials 2004; 25:887–94.

73. Ashton RS, Banerjee A, Punjany S, Schaffer DV, Kane RS: Scaffolds based on degradable alginate hydrogels and poly(lactide-co-glycolide) microspheres for stem cell culture. Biomaterials 2007; 28:5518–25.

74. Zhao LA, Wei MD, Xu HHK: An injectable calcium phosphate–alginate hydrogel–umbilical cordmesenchymalstem cell paste for bone tissue engineering. Biomaterials 2010; 31:6502–10.

75. Kuo CK, Ma PX: I onically cross linked alginate hydrogels as scaf-folds for tissue engineering: part 1. Structure, gelation rate and mechanical properties. Biomaterials 2001; 22:511–21.

76. Donati I, Asaro F, Paolletti S: Experimental evidence of counter ion affinity in alginites: the case of non-gelling ion Mg2+. Journal of Physical Chemistry B 2009; 113:12877–86.

77. Sun JY, Zhao X, Illeperuma WR, Chaudhuri O, Oh KH, Mooney DJ, Vlassak JJ and Suo Z: Highly stretchable and tough hydrogels. Nature 2012; 6:489:133.
78. Lee KY, Mooney and DJ: Alginate: properties and biomedical applications. Progress in Polymer Science 2012; 37:106–26.
79. Igarashi T, Iwasaki N, Kawamura D, Tsukuda Y, Kasahara Y, TodoH M, Tadano S, and Minami A: Therapeutic effects of intra-articular ultra-purified low endotoxin alginate administration on experimental osteoarthritis in rabbits. Cartilage 2012; 3:70–8.
80. Berger J, Reist M, Mayer JM, Felt O and Gurny R: Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. European Journal of Pharmaceutics and Biopharmaceutics 2004; 57:35–52.
81. Molinaro G, Leroux JC, Damas J and Adam A: Biocompatibility of thermosensitive chitosan-based hydrogels: an in vivo experimental approach to injectable biomaterials. Biomaterials 2002; 23:2717–22.
82. Chen A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD, Leroux JC, Atkinson BL, Binette F and Selmani A: Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Bio-materials 2000; 21:2155–61.
83. Tan HP and Marra KG: Injectable biodegradable hydrogels for tissue engineering applications. Materials 2010; 3: 1746–94.
84. Yan JH, Yang L, Wang GR, Xiao Y, Zhang BH and Qi NM: Biocompatibility evaluation of chitosan-based injectable hydrogels for the culturing mice mesenchymal stem cells in vitro. Journal of Biomaterials Applications 2010; 24:625–37.
85. Klouda L, Mikos AG: Thermoresponsive hydrogels in biomedical applications. European Journal of Pharmaceutics and Biopharmaceutics 2008; 68:34–45.
86. Stile RA and Healy KE: Thermo-responsive peptide-modified hydrogels for tissue regeneration. Biomacromolecules 2001; 2:185–94.
87. Ruel-Gariepy E and Leroux JC: In situ-forming hydrogels – review of temperature-sensitive systems. European Journal of Pharmaceutics and Biopharmaceutics 2004; 58:409–26.
88. Alexandridis P, Zhou DL and Khan A: Lyotropic liquid crystallinity in amphiphilic block copolymers: temperature effects on phase behavior and structure for poly (ethylene oxide)-b-poly(propyleneoxide)-b-poly(ethylene oxide) copolymers of different composition. Langmuir 1996; 12:2690–700.
89. Zhang XZ, Wu DQ, Sun GM, Chu CC. Novel biodegradable and thermosensitive Dex-Al/PNIPA. A hydrogel: Macromolecular Bioscience 2003; 3: 87–91.
90. Ha DI, Lee SB, Chong MS, Lee YM, Kim SY, Park YH: Preparation of thermoresponsive and injectable hydrogels based on hyaluronic acid and poly (N-isopropylacrylamide) and their drug release behaviors. Macromol Res 2006; 14:87–93.
91. Peng L, Hao JY, Xiong CD, Deng XM: A novel biodegradable and thermosensitive polymer with PEG-analogue macromolecular structure. Chemical Communications 2009; 29:4411–3.
92. Fusco S, Borzacchiello A, Netti PA: Perspectives on: PEO–PPO–PEO triblock copolymers and their biomedical applications. Journal of Bioactive and Compatible Polymers 2006; 21:149–64.
93. Jeong B, Bae YH, Kim SW: In situ gelation of PEG–PLGA–PEG triblock copolymer aqueous solutions and degradation thereof. Journal of Biomedical Material Research 2000; 50:171–7.
94. DiSibhanchong S, Radinahamed P, Stichantrakul W, Hongeng S, Rajatana V: Chronic metabolic acidosis alters osteoblast differentiation from human mesenchymal stem cells. Kidney International 2007; 71:201–209.
95. Liu H, Slomovich EB and Webster TJ: Less harmful acidic degradation of poly(lacticco-glycolic acid) bone tissue engineering scaffolds through titania nanoparticle addition. International Journal of Nanomedicine 2006; 1:541–545.
96. Xu XD, Zhang XZ, Cheng SX, Zhuo RX, Kennedy JF: A strategy to introduce the pH sensitivity to temperature sensitive PNIPAAm hydrogels without weakening the thermosensitivity. Carbohydrate Polymers 2007; 68:416–23.
97. Kim HK, Shin WS, Kim SE, Lee KH, Kang E, Kim JH, Kwon IC and Lee DS: Injectable in situ-forming /thermo-sensitive hydrogel for bone tissue engineering. Tissue Engineering 2009; 15:923–33.
98. Potta T, Chun C, Song SC: Dual cross-linking systems of functionally photo-cross-linkable and thermoresponsive polyphosphazene hydrogels for biomedical applications. Biomacromolecules 2010; 11:1741–53.
99. Tai H, Howard D, Takae S, Wang W, Vermondon T, Hennink WE, Stayton PS, Hoffman AS, Endruweit A, Alexander C, Howdle SM, and Shakesheff KM: Photo-cross-linked hydrogels from thermoresponsive PEG/MMA–PPGMA–EGDMA copolymers containing multiple methacrylate groups: mechanical property, swelling, protein release, and cytotoxicity. Biomacromolecules 2009; 10:2895–903.
100. Salem AK, Rose FRAJ, Oreffo ROC, Yang XB, Davies MC, Mitchell JR, Roberts CJ, Stolnik-Trenkic S, Tendler SJ, Williams PM, Shakesheff KM: Porous polymer and cell composites that self-assemble in situ. Advanced Material 2003; 15:210–3.
101. Foo CTSWP, Lee JS, Mulyasasmita W, Parisi-Amon A, Heilshorn SC: Two-component protein-engineered physical hydrogels for cell encapsulation. Proceedings of the National Academy of Sciences USA 2009; 106:22067–72.
102. Kicik KL: Peptide- and protein-mediated assembly of heparinized hydrogels. Soft Matter 2008; 4:29–37.
103. Miyata T, Asami N, Uragami T: Structural design of stimuli-responsivebioconjugated hydrogels that respond to a target antigen. Journal of Polymer Science part B Polymer Physics 2009; 47:2144–57.
104. Miyata T, Asami N and Uragami T: Preparation of an antigen-sensitive hydrogel using antigen–antibody bindings. Macromolecules 1999; 32:2082–4.
105. Miyata T, Asami N, Uragami T: A reversibly antigen-responsive hydrogel. Nature 1999; 399:766–9.
106. Um SH, Lee JB, Park N, Kwon SY, Umbach CC, Luo D: Enzyme-catalysed assembly of DNA hydrogel. Nature Materials 2006; 5:797–801.
107. Xing YZ, Cheng EJ, Yang Y, Chen P, Zhang T, Sun YW, Yang ZQ and Liu DS: Self-assembled DNA hydrogels with designable thermal and enzymatic responsiveness. Advanced Materials 2011; 23:1117–21.
108. Wei B, Cheng I, Luo KQ and Mi YL: Capture and release of protein by a reversible DNA-induced sol-gel transition system. Angewandte Chemie International Edition 2008; 47:331–3.
109. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nature Reviews Drug Discovery 2004; 3:1023–35.
110. Li J: Self-assembled supramolecular hydrogels based on polymer–cyclodextrin inclusion complexes for drug delivery. NPG Asia Materials 2010; 2:112–8.
111. Kretschmann O, Choi SW, Miyauchi M, Tomatsu I, Harada A, Ritter H: Switchable hydrogels obtained by supramolecular cross-linking of adamantyl-containing LCST copolymers with cyclodextrinimidines. Angewandte Chemie International Edition 2006; 45:4361–4365.
112. Van de Manakker F, van der Pot M, Vermonden T, van Nostrum CF and Hennink WE: Self-assembling hydrogels based on beta-cyclodextrin/cholesterol inclusion complexes. Macromolecules 2008; 41:1766–1773.
113. Lehn J-M: From molecular to supramolecular chemistry. In: Supramolecular chemistry. Weinheim: Wiley-VCH; 1995. 1–9.
114. Bilensoy E, Rouf MA, Vural I, Sen M, Hincal AA: Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole:beta-cyclodextrin complex. AAPS PharmSciTech. 2006;7(2):E38.
115. Dholakia M, Thakkar V, Patel N, Gandhi T: Development and characterisation of thermo reversible mucoadhesive moxifloxacin hydrochloride in situ ophthalmic gel. Journal of Pharmacy and Bio allied Science. 2012; 4:S42–S45.
116. Jung YS, Park W, Park H, Lee D.K, & Na K: Thermo-sensitive injectable hydrogel based on the physical mixing of hyaluronic acid and Pluronic F-127 for sustained NSAID delivery. Carbohydrate Polymers 2017; 156: 403–408.
117. Yong C.S, Choi J.S, Quan Q.-Z, Rhee J.D, Kim C.K, Lim S.J, Kim K.M, Oh P.S., Choi S.G: Effect of sodium chloride on the gelation temperature, gel strength and bioadhesive force of poloxamer gels containing diclofenac sodium. International Journal of Pharmaceutics 2001; 226: 195–205.
118. Hiemstra C., Zhong Z, Van Tomme SR, van Steenbergen MJ, Jacobs JJ, Den Otter W, Hennink WE, Feijen J: In vitro and in vivo protein delivery from in situ forming poly (ethylene glycol)–poly (lactide) hydrogels. Journal of Controlled Release 2007; 119:320–327.
119. Jiang T, Sun C, Shen X, Wang T, Wang S: Development of a poloxamer analogs/bioadhesive polymers-based in situ gelling ophthalmic delivery system for tiopronin. Journal of Applied Polymer Science 2009; 114: 775–783.
120. Xuan JJ, Balakrishnan P, Oh DH, Yeo WH, Park SM, Yong CS and Choi S.G: Rheological characterization and in vivo evaluation of thermosensitive poloxamer-based hydrogel for intramuscular injection of piroxicam. International Journal of Pharmaceutics 2010; 395:317–23.
121. Fu S, Ni P, Wang B, Chu B, Zheng L, Luo F & Qian Z: Injectable and thermo-sensitivePEG-PCL-PEG copolymer/collagen/n-HA hydrogel composite for guided bone regeneration. Biomaterials 2010; 31: 4801–4809.
122. Mandal B. B, Priya A S, & Kundu, S C: Novel silk sericin/gelatin 3-D scaffolds and 2-D films: Fabrication and characterization for potential tissue engineering applications. Acta Biomaterialia 2009; 5: 3007–3020.
123. Domingos M., Chiellini F, Cometa S, De Giglio E, Grillo-Fernandes E., & Bártolo, P: Evaluation of in vitro degradation of PCL scaffolds fabricated via Bio Extrusion. Part 1: Influence of the degradation environment. Virtual and Physical Prototyping 2010; 5: 65–73.
124. Fu A, Gwon K, Kim M, Tae G, & Kornfield, J A: Visible-light-initiated thiol–acrylate photopolymerization of heparin-based hydrogels. Biomacromolecules, 2015; 16: 497–506.
125. Siepmann J, Peppas N: Modeling of drug release from delivery systems based on hydroxypropylmethylcellulose (HPMC). Advanced Drug Delivery Reviews 2012; 64: 163–74.
126. Roughley, P, Hoemann, C., DesRosiers, E., Mwale, F., Antoniou, J, Alini, M: The potential of chitosan-based gels containing intervertebral disc cells for nucleus pulposus supplementation. Biomaterials 2006; 27: 388–396.
127. Nirmal, H.B, Bakliwal, S.R., Pawar, S.P: In-situ gel: new trends in controlled and sustained drug delivery system. International Journal of PharmTech. Research 2010; 2: 1398–1408.
128. Song J, Bi H, Xie X, Guo J, Wang X., Liu D.: Preparation and evaluation of sinomenine hydrochloride in situ gel for uveitis treatment. International Immunopharmacology 2013; 17: 99–107.
129. Xiang NX, Zhou X, HeXY, ZhangY, ZhangJJ, ZhangZR: An injectable gel platform for the prolonged therapeutic effect of pitavastatin in the management of hyperlipidemia. Journal of pharmaceutical sciences 2016; 105: 1148–55.
130. Abashzadeh Sh, Dinarvand R, Sharifzadeh M, Hassanzadeh G, Amini M, Atyabi F: Formulation and evaluation of an in situ gel forming system for controlled delivery of triptorelin acetate. European Journal of Pharmaceutical Sciences 2011 44: 514–521.
131. Gohl M, Kim1 Y, Gwon K, Min K, Hwang Y, Giyoong T: In situ formation of injectable and porous heparin-based hydrogel. Carbohydrate Polymers 2017; 174: 990–998.